NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Apollo Hospitals Enterprise Reports Strong Growth in Q4FY26 and FY26 Financial Results

Apollo Hospitals Enterprise, one of the country's largest private hospital chains, announced its March quarter and FY26 financial results on May 20 after market hours, reporting robust growth in revenue and EBITDA across all three business verticals as well as at the consolidated level.

The company posted a 36% year-on-year (YoY) rise in consolidated net profit to ₹529 crore, compared to ₹389 crore in the same quarter last year. On the top line, revenue grew 18% YoY to ₹6,605 crore from ₹5,592 crore reported in the corresponding period last year.

At the operating level, EBITDA stood at ₹1,011 crore, marking a 31.5% YoY increase compared to ₹769 crore in Q4FY25, while EBITDA margins expanded by 154 basis points to 15.3%.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

SegmentQ4FY26 RevenueQ4FY25 RevenueYoY Growth
Healthcare Services₹3,268 crore₹2,813 crore16%
Apollo Health and Lifestyle₹489 crore₹396 crore24%
Apollo HealthCo₹2,848 crore₹2,372 crore20%

In terms of segments, the healthcare services division posted 16% YoY revenue growth to ₹3,268 crore, while EBITDA rose 14% to ₹781 crore with margins at 23.9%. Apollo Health and Lifestyle delivered a strong performance, with revenue increasing 24% YoY to ₹489 crore and EBITDA surging 58% to ₹75 crore. The segment also turned profitable, reporting a PAT of ₹10 crore against a loss of ₹4 crore a year before.

Meanwhile, Apollo HealthCo reported 20% YoY revenue growth at ₹2,848 crore, while EBITDA jumped sharply to ₹156 crore from ₹36 crore in Q4FY25. PAT for the segment rose significantly to ₹107 crore from ₹9 crore last year.

For the full financial year FY26, the company reported consolidated revenue growth of 16% YoY to ₹25,229 crore from ₹21,794 crore in FY25. EBITDA rose to ₹3,769 crore from ₹3,022 crore in the previous fiscal, despite Apollo 24/7-related costs of ₹467 crore during the year, including a non-cash ESOP charge of ₹118 crore.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

On the bottom line, the net profit increased to ₹1,942 crore from ₹1,446 crore in FY25. Meanwhile, the gross merchandise value (GMV) of Apollo 24/7 stood at ₹2,037 crore during FY26.

The company announced a final dividend of ₹10 per share for FY26 and fixed Friday, August 14, 2026, as the record date to determine eligible shareholders entitled to receive the dividend, as well as for participation in the Annual General Meeting (AGM).

The Board of Directors recommended a final dividend of ₹10 per equity share (200%) of the face value of ₹5 per share for FY2025-26. The dividend recommended by the Board is subject to the approval of shareholders at the ensuing Annual General Meeting of the Company.

Investor Takeaway

Apollo Hospitals reported a 36% YoY rise in net profit to ₹529 crore in Q4, indicating strong growth in revenue and EBITDA.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.